Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

PROEHL GERALD T

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [DRMA]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
President, CEO and Chairman

(Last)

(First)

(Middle)

3525 DEL MAR HEIGHTS RD., #332

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2021

(Street)

SAN DIEGO, CA 92130

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/16/2021		P		10,000	A	$ 4.9631 ⁽¹⁾	10,000	I	By Proehl Family Trust ⁽⁸⁾
Common Stock	08/17/2021		C		17,857	A	⁽²⁾	17,857	I	By Allison Taylor Proehl 2020 Irrevocable Trust ⁽⁸⁾
Common Stock	08/17/2021		C		8,928	A	⁽²⁾	8,928	I	By Meghan Proehl Wilder 2020 Irrevocable Trust ⁽⁸⁾
Common Stock	08/17/2021		C		35,767	A	⁽²⁾	35,767	I	By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 ⁽⁸⁾
Common Stock	08/17/2021		C		361,147	A	⁽²⁾	1,278,464	I	By Proehl Investment Ventures LLC ⁽⁸⁾
Common Stock	08/17/2021		C		111,951	A	⁽³⁾	1,390,415	I	By Proehl Investment Ventures LLC ⁽⁸⁾
Common Stock	08/17/2021		C		181,585	A	⁽⁴⁾	1,572,000	I	By Proehl Investment Ventures LLC ⁽⁸⁾
Common Stock	08/17/2021		C		1,247,904	A	⁽⁵⁾	2,819,904	I	By Proehl Investment Ventures LLC ⁽⁸⁾
Common Stock	08/17/2021		C		85,640	A	⁽⁶⁾	2,905,544	I	By Proehl Investment Ventures LLC ⁽⁸⁾
Common Stock	08/17/2021		P		142,857	A	⁽⁹⁾	152,857	I	By Proehl Family Trust ⁽⁸⁾
Common Stock								39,512	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series 1d Preferred Stock

⁽²⁾

08/17/2021

120,481

⁽²⁾

Common Stock

17,857

$ 0

By Allison Taylor Proehl 2020 Irrevocable Trust ⁽⁸⁾

Series 1d Preferred Stock

⁽²⁾

08/17/2021

60,240

⁽²⁾

Common Stock

8,928

$ 0

By Meghan Proehl Wilder 2020 Irrevocable Trust ⁽⁸⁾

Series 1d Preferred Stock

⁽²⁾

08/17/2021

241,325

⁽²⁾

Common Stock

35,767

$ 0

By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 ⁽⁸⁾

Series 1d Preferred Stock

⁽²⁾

08/17/2021

2,436,657

⁽²⁾

Common Stock

361,147

$ 0

By Proehl Investment Ventures LLC ⁽⁸⁾

Series 1a Preferred Stock

⁽³⁾

08/17/2021

2,295,000

⁽³⁾

Common Stock

111,951

$ 0

By Proehl Investment Ventures LLC ⁽⁸⁾

Series 1b Preferred Stock

⁽⁴⁾

08/17/2021

3,722,500

⁽⁴⁾

Common Stock

181,585

$ 0

By Proehl Investment Ventures LLC ⁽⁸⁾

Series 1c Preferred Stock

⁽⁵⁾

08/17/2021

25,582,050

⁽⁵⁾

Common Stock

1,247,904

$ 0

By Proehl Investment Ventures LLC ⁽⁸⁾

Series 1 Preferred Stock

⁽⁶⁾

08/17/2021

1,755,622

⁽⁶⁾

Common Stock

85,640

$ 0

By Proehl Investment Ventures LLC ⁽⁸⁾

Series 1a Warrants

⁽⁷⁾

08/17/2021

573,750

11/15/2016

03/14/2026

Common Stock

27,987

$ 0

By Proehl Investment Ventures LLC ⁽⁸⁾

Warrant to Purchase Common Stock

$ 20.5

08/17/2021

27,987

11/15/2016

03/14/2026

Common Stock

27,987

$ 0

27,987

By Proehl Investment Ventures LLC ⁽⁸⁾

Warrant to Purchase Common Stock

$ 7

08/17/2021

142,857

08/17/2021

08/17/2026

Common Stock

142,857

⁽⁹⁾

142,857

By Proehl Family Trust ⁽⁸⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
PROEHL GERALD T 3525 DEL MAR HEIGHTS RD., #332 SAN DIEGO, CA 92130	X	X	President, CEO and Chairman

Signatures

/s/ Gerald T. Proehl		08/17/2021
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
(2)	The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
(3)	The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
(4)	The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
(5)	The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
(6)	The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
(7)	The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.
(8)	Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
(9)	Reporting Person purchased 142,857 Units in the IPO at $7.00 per Unit Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.